Improving survival among men with oligorecurrent prostate cancer?

A newly published article in the Journal of Clinical Oncology reports data from a small, randomized, multicenter, Phase II clinical trial comparing active monitoring to treatment of men with recurrent, asymptomatic, oligometastatic prostate cancer. … READ MORE …

Serial mpMRIs instead of serial biopsies for men on active surveillance

The role of baseline and repeat multiparametric MRI (mpMRI) scanning as a substitute for repeat biopsies in the initial evaluation and ongoing management of men on active surveillance continues to evolve. … READ MORE …

The role of 3 T mpMRI in monitoring men on active surveillance

A newly published paper in the American Journal of Roetgenology provides an early data set on the application of 3 T multiparameric MRI scans in monitoring men on active surveillance (as opposed to the use of serial biopsies). … READ MORE …

The initial (10-year) results of the ProtecT trial: much as we might have expected?

So the majority of the readers of The “New” Prostate Cancer InfoLink will be well aware that we have never had data from a large, randomized clinical trial comparing the outcomes of the commonest first-line forms of management of men diagnosed with localized prostate cancer … READ MORE …

Estimation of life expectancy for newly diagnosed men with prostate cancer

A critical question for every patient newly diagnosed with prostate cancer is going to be, “How long am I going to live”? That question may be particularly important if a second and associated question is, “How long am I going to live if I just monitor my cancer on active surveillance or watchful waiting?” … READ MORE …

From the past to the future … the appropriate use of active monitoring

A new article just published in the journal Cancer concludes that “active surveillance is underused” in the management of low-risk prostate cancer. However, one has to be careful about how one interpret the data in (and the conclusions of) this particular article. … READ MORE …

The screening/testing debate is alive and healthy!

An open access (i.e., full text) article just published in BMC Medicine provides us with a detailed discussion of the current state of the PSA-based “screening/testing” debate as seen from the differing perspectives of a number of academic experts on this topic. … READ MORE …